Modelling bladder cancer in mice: Opportunities and challenges

Nature Reviews Cancer

Volumn 15, Issue 1, 2015, Pages 42-54

  Kobayashi, Takashi ^a   Owczarek, Tomasz B ^b   McKiernan, James M ^b   Abate Shen, Cory ^b,c  

^a KYOTO UNIVERSITY   (Japan)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN;

BLADDER CANCER; CANCER CELL; CANCER PROGNOSIS; CANCER THERAPY; GENETICALLY ENGINEERED MOUSE STRAIN; LANDSCAPE; MOUSE; MOUSE MODEL; MUSCLE INVASIVE BLADDER CANCER; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSGENIC ORGANISM; TUMOR ENGRAFTMENT; ANIMAL; CANCER TRANSPLANTATION; DISEASE MODEL; HUMAN; PATHOLOGY; TRANSGENIC MOUSE; TUMOR GENE; TUMOR INVASION; URINARY BLADDER NEOPLASMS;

ANIMALS; DISEASE MODELS, ANIMAL; GENES, NEOPLASM; HUMANS; MICE; MICE, TRANSGENIC; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; URINARY BLADDER NEOPLASMS;

EID: 84925546188     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3858     Document Type: Review

References (160)

1. Kaufman, D. S., Shipley, W. U. & Feldman, A. S. Bladder cancer. Lancet 374, 239-249 (2009).
2. Dinney, C. P. et al. Focus on bladder cancer. Cancer Cell 6, 111-116 (2004).
3. Prasad, S. M., Decastro, G. J. & Steinberg, G. D. & Medscape. Urothelial carcinoma of the bladder: definition, treatment and future efforts. Nature Rev. Urol. 8, 631-642 (2011).
4. Botteman, M. F., Pashos, C. L., Redaelli, A., Laskin, B. & Hauser, R. The health economics of bladder cancer: a comprehensive review of the published literature. PharmacoEconomics 21, 1315-1330 (2003).
5. Hicks, R. M. The mammalian urinary bladder: an accommodating organ. Biol. Rev. Camb. Phil. Soc. 50, 215-246 (1975).
6. Bradley, W. E. & Long, D. M. Morphology of the developing mammalian bladder. Invest. Urol. 7, 66-73 (1969).
7. Baskin, L. S., Hayward, S. W., Young, P. F. & Cunha, G. R. Ontogeny of the rat bladder: smooth muscle and epithelial differentiation. Acta Anatom. 155, 163-171 (1996).
8. De La Rosette, J., Smedts, F., Schoots, C., Hoek, H. & Laguna, P. Changing patterns of keratin expression could be associated with functional maturation of the developing human bladder. J. Urol. 168, 709-717 (2002).
9. Khandelwal, P., Abraham, S. N. & Apodaca, G. Cell biology and physiology of the uroepithelium. Am. J. Physiol. Renal Physiol. 297, F1477-E1501 (2009).
10. Castillo-Martin, M., Domingo-Domenech, J., Karni-Schmidt, O., Matos, T. & Cordon-Cardo, C. Molecular pathways of urothelial development and bladder tumorigenesis. Urol. Oncol. 28, 401-408 (2010).
11. Sun, W., Wilhelmina Aalders, T. & Oosterwijk, E. Identification of potential bladder progenitor cells in the trigone. Dev. Biol. 393, 84-92 (2014).
12. Wu, X. R., Kong, X. P., Pellicer, A., Kreibich, G. & Sun, T. T. Uroplakins in urothelial biology, function, and disease. Kidney Int. 75, 1153-1165 (2009).
13. Messier, B. & Leblond, C. P. Cell proliferation and migration as revealed by radioautography after injection of thymidine-H3 into male rats and mice. Am. J. Anat. 106, 247-285 (1960).
14. Jost, S. P. & Potten, C. S. Urothelial proliferation in growing mice. Cell Tissue Kinet. 19, 155-160 (1986).
15. Cooper, E. H., Cowen, D. M. & Knowles, J. C. The recovery of mouse bladder epithelium after injury by 4-ethylsulphonylnaphthalene-1-sulphonamide. J. Pathol. 108, 151-156 (1972).
16. Lavelle, J. et al. Bladder permeability barrier: recovery from selective injury of surface epithelial cells. Am. J. Physiol. Renal Physiol. 283, F242-253 (2002).
17. Mysorekar, I. U., Isaacson-Schmid, M., Walker, J. N., Mills, J. C. & Hultgren, S. J. Bone morphogenetic protein 4 signaling regulates epithelial renewal in the urinary tract in response to uropathogenic infection. Cell Host Microbe 5, 463-475 (2009).
18. Shin, K. et al. Hedgehog/Wnt feedback supports regenerative proliferation of epithelial stem cells in bladder. Nature 472, 110-114 (2011).
19. Ho, P. L., Kurtova, A. & Chan, K. S. Normal and neoplastic urothelial stem cells: getting to the root of the problem. Nature Rev. Urol. 9, 583-594 (2012).
20. Gandhi, D. et al. Retinoid signaling in progenitors controls specification and regeneration of the urothelium. Dev. Cell 26, 469-482 (2013).
21. Colopy, S. A., Bjorling, D. E., Mulligan, W. A. & Bushman, W. A population of progenitor cells in the basal and intermediate layers of the murine bladder urothelium contributes to urothelial development and regeneration. Dev. Dyn. 243, 988-998 (2014).
22. Karni-Schmidt, O. et al. Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. Am. J. Pathol. 178, 1350-1360 (2011).
23. Signoretti, S. et al. p63 regulates commitment to the prostate cell lineage. Proc. Natl Acad. Sci. USA 102, 11355-11360 (2005).
24. Gaisa, N. T. et al. The human urothelium consists of multiple clonal units, each maintained by a stem cell. J. Pathol. 225, 163-171 (2011).
25. Dahm, P. & Gschwend, J. E. Malignant non-urothelial neoplasms of the urinary bladder: a review. Eur. Urol. 44, 672-681 (2003).
26. Williamson, S. R. et al. Diagnosis, evaluation and treatment of carcinoma in situ of the urinary bladder: the state of the art. Crit. Rev. Oncol. Hematol. 76, 112-126 (2010).
27. Nese, N., Gupta, R., Bui, M. H. & Amin, M. B. Carcinoma in situ of the urinary bladder: review of clinicopathologic characteristics with an emphasis on aspects related to molecular diagnostic techniques and prognosis. J. Natl Compr. Canc. Netw. 7, 48-57 (2009).
28. Shin, K. et al. Cellular origin of bladder neoplasia and tissue dynamics of its progression to invasive carcinoma. Nature Cell Biol. 16, 469-478 (2014).
29. He, X. et al. Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma. Stem Cells 27, 1487-1495 (2009).
30. Chan, K. S. et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc. Natl Acad. Sci. USA 106, 14016-14021 (2009).
31. Volkmer, J. P. et al. Three differentiation states risk-stratify bladder cancer into distinct subtypes. Proc. Natl Acad. Sci. USA 109, 2078-2083 (2012).
32. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315-322 (2014).
33. Choi, W. et al. Identification of distinct Basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25, 152-165 (2014).
34. Damrauer, J. S. et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc. Natl Acad. Sci. USA 111, 3110-3115 (2014).
35. Choi, W. et al. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nature Rev. Urol. 11, 400-410 (2014).
36. Van Batavia, J. et al. Bladder cancers arise from distinct urothelial sub-populations. Nature Cell Biol. 16, 982-991 (2014).
37. Dancik, G. M., Owens, C. R., Iczkowski, K. A. & Theodorescu, D. A cell of origin gene signature indicates human bladder cancer has distinct cellular progenitors. Stem Cells 32, 974-982 (2014).
38. Resnick, M. J., Bassett, J. C. & Clark, P. E. Management of superficial and muscle-invasive urothelial cancers of the bladder. Curr. Opin. Oncol. 25, 281-288 (2013).
39. Clark, P. E. et al. Bladder cancer. J. Natl Compr. Canc. Netw. 11, 446-475 (2013).
40. Redelman-Sidi, G., Glickman, M. S. & Bochner, B. H. The mechanism of action of BCG therapy for bladder cancer-a current perspective. Nature Rev. Urol.11, 153-162 (2014).
41. Gontero, P. et al. The role of bacillus Calmette-Guerin in the treatment of non-muscle-invasive bladder cancer. Eur. Urol. 57, 410-429 (2010).
42. Herr, H. W. & Morales, A. History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J. Urol. 179, 53-56 (2008).
43. Barlow, L. J., Seager, C. M., Benson, M. C. & McKiernan, J. M. Novel intravesical therapies for non-muscle-invasive bladder cancer refractory to BCG. Urol. Oncol. 28, 108-111 (2010).
44. Dash, A. et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer 113, 2471-2477 (2008).
45. Zargar, H. et al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur. Urol. 23 Sept 2014 (doi:10.1016/j.eururo.2014.09.007).
46. Stein, J. P. et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol. 19, 666-675 (2001).
47. Singer, S. et al. Quality of life in patients with muscle invasive and non-muscle invasive bladder cancer. Support. Care Cancer 21, 1383-1393 (2013).
48. Somani, B. K., Gimlin, D., Fayers, P. & N'Dow, J. Quality of life and body image for bladder cancer patients undergoing radical cystectomy and urinary diversion-a prospective cohort study with a systematic review of literature. Urology 74, 1138-1143 (2009).
49. Wu, X., Hildebrandt, M. A. & Chang, D. W. Genome-wide association studies of bladder cancer risk: a field synopsis of progress and potential applications. Cancer Metastasis Rev. 28, 269-280 (2009).
50. Freedman, N. D., Silverman, D. T., Hollenbeck, A. R., Schatzkin, A. & Abnet, C. C. Association between smoking and risk of bladder cancer among men and women. JAMA 306, 737-745 (2011).
51. Kiriluk, K. J., Prasad, S. M., Patel, A. R., Steinberg, G. D. & Smith, N. D. Bladder cancer risk from occupational and environmental exposures. Urol. Oncol. 30, 199-211 (2012).
52. Burger, M. et al. Epidemiology and risk factors of urothelial bladder cancer. Eur. Urol. 63, 234-241 (2013).
53. Mitra, A. P. & Cote, R. J. Molecular pathogenesis and diagnostics of bladder cancer. Ann. Rev. Pathol. 4, 251-285 (2009).
54. Crivelli, J. J. et al. Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature. Eur. Urol. 65, 742-754 (2014).
55. Baskin, L. S., Hayward, S. W., Young, P. & Cunha, G. R. Role of mesenchymal-epithelial interactions in normal bladder development. J. Urol. 156, 1820-1827 (1996).
56. Marcinkiewicz, K. et al. The androgen receptor and stem cell pathways in prostate and bladder cancers (review). Int. J. Oncol. 40, 5-12 (2012).
57. Hsu, J. W. et al. Decreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor. Am. J. Pathol. 182, 1811-1820 (2013).
58. Lin, C. et al. Constitutive β-catenin activation induces male-specific tumorigenesis in the bladder urothelium. Cancer Res. 73, 5914-5925 (2013).
59. Knowles, M. A. Molecular pathogenesis of bladder cancer. Int. J. Clin. Oncol. 13, 287-297 (2008).
60. Goebell, P. J. & Knowles, M. A. Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. Urol. Oncol. 28, 409-428 (2010).
61. Wu, X. R. Urothelial tumorigenesis: a tale of divergent pathways. Nature Rev. Cancer 5, 713-725 (2005).
62. Esrig, D. et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. New Engl. J. Med. 331, 1259-1264 (1994).
63. Dyrskjot, L. et al. Identifying distinct classes of bladder carcinoma using microarrays. Nature Genet. 33, 90-96 (2003).
64. Sanchez-Carbayo, M. et al. Gene discovery in bladder cancer progression using cDNA microarrays. Am. J. Pathol. 163, 505-516 (2003).
65. Blaveri, E. et al. Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin. Cancer Res. 11, 7012-7022 (2005).
66. Kim, J. H. et al. Alterations in transcription clusters underlie development of bladder cancer along papillary and nonpapillary pathways. Lab. Invest. 85, 532-549 (2005).
67. Mitra, A. P. et al. Generation of a concise gene panel for outcome prediction in urinary bladder cancer. J. Clin. Oncol. 27, 3929-3937 (2009).
68. Riester, M. et al. Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clin. Cancer Res.18, 1323-1333 (2012).
69. Lauss, M., Ringner, M. & Hoglund, M. Prediction of stage, grade, and survival in bladder cancer using genome-wide expression data: a validation study. Clin. Cancer Res. 16, 4421-4433 (2010).
70. Lindgren, D. et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res. 70, 3463-3472 (2010).
71. Zieger, K., Marcussen, N., Borre, M., Orntoft, T. F. & Dyrskjot, L. Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development. International journal of cancer. J. Int. Cancer 125, 2095-2103 (2009).
72. Hurst, C. D., Platt, F. M., Taylor, C. F. & Knowles, M. A. Novel tumor subgroups of urothelial carcinoma of the bladder defined by integrated genomic analysis. Clin. Cancer Res. 18, 5865-5877 (2012).
73. Lindgren, D. et al. Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma. PLoS One 7, e38863 (2012).
74. Sjodahl, G. et al. A molecular taxonomy for urothelial carcinoma. Clin. Cancer Res.18, 3377-3386 (2012).
75. Nordentoft, I. et al. Mutational context and diverse clonal development in early and late bladder cancer. Cell Rep. 7, 1649-1663 (2014).
76. Gui, Y. et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nature Genet. 43, 875-878 (2011).
77. Morrison, C. D. et al. Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer. Proc. Natl Acad. Sci. USA 111, E672-E681 (2014).
78. Ross, J. S. et al. Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy. Modern Pathol. 27, 271-280 (2014).
79. Guo, G. et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nature Genet. 45, 1459-1463 (2013).
80. Cazier, J. B. et al. Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden. Nature Commun. 5, 3756 (2014).
81. Iyer, G. et al. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J. Clin. Oncol. 31, 3133-3140 (2013).
82. Iyer, G. et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 338, 221 (2012).
83. Wagle, N. et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 4, 546-553 (2014).
84. Shih, C. & Weinberg, R. A. Isolation of a transforming sequence from a human bladder carcinoma cell line. Cell 29, 161-169 (1982).
85. Santos, E., Tronick, S. R., Aaronson, S. A., Pulciani, S. & Barbacid, M. T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes. Nature 298, 343-347 (1982).
86. Reddy, E. P., Reynolds, R. K., Santos, E. & Barbacid, M. A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature 300, 149-152 (1982).
87. Gust, K. M. et al. Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer. Mol. Cancer Ther. 12, 1245-1254 (2013).
88. Rebouissou, S. et al. EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Sci. Transl. Med. 6, 244ra291 (2014).
89. Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333-339 (2013).
90. Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495-501 (2014).
91. de Visser, K. E., Eichten, A. & Coussens, L. M. Paradoxical roles of the immune system during cancer development. Nature Rev. Cancer 6, 24-37 (2006).
92. Degraff, D. J. et al. Current preclinical models for the advancement of translational bladder cancer research. Mol. Cancer Ther. 12, 121-130 (2013).
93. Ahmad, I., Sansom, O. J. & Leung, H. Y. Exploring molecular genetics of bladder cancer: lessons learned from mouse models. Dis. Model Mech. 5, 323-332 (2012).
94. Ding, J. et al. Current animal models of bladder cancer: Awareness of translatability (Review). Exp. Ther. Med. 8, 691-699 (2014).
95. Druckrey, H. et al. Selective induction of bladder cancer in rats by dibutyl- and N-butyl-N-butanol(4)-nitrosamine. Zeitschrift Krebsforschung 66, 280-290 (1964).
96. Hicks, R. M. & Wakefield, J. S. Rapid induction of bladder cancer in rats with N-methyl-N-nitrosourea. I. Histology. Chem. Biol. Interact. 5, 139-152 (1972).
97. Fukushima, S., Hirose, M., Tsuda, H., Shirai, T. & Hirao, K. Histological classification of urinary bladder cancers in rats induced by N-butyl-n-(4-hydroxybutyl)nitrosamine. Gann. 67, 81-90 (1976).
98. Cohen, S. M. Urinary bladder carcinogenesis. Toxicol. Pathol. 26, 121-127 (1998).
99. Soloway, M. S. Single and combination chemotherapy for primary murine bladder cancer. Cancer 36, 333-340 (1975).
100. Vasconcelos-Nobrega, C., Colaco, A., Lopes, C. & Oliveira, P. A. Review: BBN as an urothelial carcinogen. In Vivo 26, 727-739 (2012).
101. He, Z., Kosinska, W., Zhao, Z. L., Wu, X. R. & Guttenplan, J. B. Tissue-specific mutagenesis by N-butyl-N-(4-hydroxybutyl)nitrosamine as the basis for urothelial carcinogenesis. Mut. Res. 742, 92-95 (2012).
102. Yamamoto, S. et al. Frequent mutations of the p53 gene and infrequent H- and K-ras mutations in urinary bladder carcinomas of NON/Shi mice treated with N-butyl-N-(4-hydroxybutyl)nitrosamine. Carcinogenesis 16, 2363-2368 (1995).
103. Kim, S. K. et al. Identification of gene expression signature modulated by nicotinamide in a mouse bladder cancer model. PLoS One 6, e26131 (2011).
104. Williams, P. D., Lee, J. K. & Theodorescu, D. Molecular credentialing of rodent bladder carcinogenesis models. Neoplasia 10, 838-846 (2008).
105. Weldon, T. E. & Soloway, M. S. Susceptibility of urothelium to neoplastic cellular implantation. Urology 5, 824-827 (1975).
106. Oshinsky, G. S., Chen, Y., Jarrett, T., Anderson, A. E. & Weiss, G. H. A model of bladder tumor xenografts in the nude rat. J. Urol. 154, 1925-1929 (1995).
107. Gunther, J. H. et al. Optimizing syngeneic orthotopic murine bladder cancer (MB49). Cancer Res. 59, 2834-2837 (1999).
108. Xiao, Z. et al. Characterization of a novel transplantable orthotopic rat bladder transitional cell tumour model. Br. J. Cancer 81, 638-646 (1999).
109. Chan, E. S. et al. Optimizing orthotopic bladder tumor implantation in a syngeneic mouse model. J. Urol. 182, 2926-2931 (2009).
110. Dobek, G. L. & Godbey, W. T. An orthotopic model of murine bladder cancer. J. Vis. Exp. 6, 2535 (2011).
111. Oottamasathien, S. et al. Bladder tissue formation from cultured bladder urothelium. Dev. Dyn. 235, 2795-2801 (2006).
112. Puzio-Kuter, A. M. et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev. 23, 675-680 (2009).
113. Kerbel, R. S., Cornil, I. & Theodorescu, D. Importance of orthotopic transplantation procedures in assessing the effects of transfected genes on human tumor growth and metastasis. Cancer Metastasis Rev. 10, 201-215 (1991).
114. Black, P. C. et al. Validating bladder cancer xenograft bioluminescence with magnetic resonance imaging: the significance of hypoxia and necrosis. BJU Int. 106, 1799-1804 (2010).
115. van der Horst, G. et al. Real-time cancer cell tracking by bioluminescence in a preclinical model of human bladder cancer growth and metastasis. Eur. Urol. 60, 337-343 (2011).
116. Chan, E. S., Patel, A. R., Hansel, D. E., Larchian, W. A. & Heston, W. D. Sunitinib malate provides activity against murine bladder tumor growth and invasion in a preclinical orthotopic model. Urology 80, 736 (2012).
117. Chen, S. C., Henry, D. O., Hicks, D. G., Reczek, P. R. & Wong, M. K. Intravesical administration of plasminogen activator inhibitor type-1 inhibits in vivo bladder tumor invasion and progression. J. Urol. 181, 336-342 (2009).
118. Tentler, J. J. et al. Patient-derived tumour xenografts as models for oncology drug development. Nature Rev. Clin. Oncol. 9, 338-350 (2012).
119. Park, B. et al. Development and characterization of a bladder cancer xenograft model using patient-derived tumor tissue. Cancer Sci. 104, 631-638 (2013).
120. Cirone, P., Andresen, C. J., Eswaraka, J. R., Lappin, P. B. & Bagi, C. M. Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer. Cancer Chemother. Pharmacol. 73, 525-538 (2014).
121. Sharpless, N. E. & Depinho, R. A. The mighty mouse: genetically engineered mouse models in cancer drug development. Nature Rev. Drug Discov. 5, 741-754 (2006).
122. Politi, K. & Pao, W. How genetically engineered mouse tumor models provide insights into human cancers. J. Clin. Oncol. 29, 2273-2281 (2011).
123. Abate-Shen, C. & Pandolfi, P. P. Effective utilization and appropriate selection of genetically engineered mouse models for translational integration of mouse and human trials. Cold Spring Harb. Protoc. 2013, pdb.top078774 (2013).
124. Hanahan, D., Wagner, E. F. & Palmiter, R. D. The origins of oncomice: a history of the first transgenic mice genetically engineered to develop cancer. Genes Dev. 21, 2258-2270 (2007).
125. Zhang, Z. T., Pak, J., Shapiro, E., Sun, T. T. & Wu, X. R. Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. Cancer Res. 59, 3512-3517 (1999).
126. Ayala de la Pena, F. et al. Loss of p53 and acquisition of angiogenic microRNA profile are insufficient to facilitate progression of bladder urothelial carcinoma in situ to invasive carcinoma. J. Biol. Chem. 286, 20778-20787 (2011).
127. Stone, R. 2nd et al. Identification of genes correlated with early-stage bladder cancer progression. Cancer Prev. Res. 3, 776-786 (2010).
128. Grippo, P. J. & Sandgren, E. P. Highly invasive transitional cell carcinoma of the bladder in a simian virus 40 T-antigen transgenic mouse model. Am. J. Pathol. 157, 805-813 (2000).
129. He, F. et al. Deficiency of pRb family proteins and p53 in invasive urothelial tumorigenesis. Cancer Res. 69, 9413-9421 (2009).
130. Zhang, Z. T. et al. Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene 20, 1973-1980 (2001).
131. Cheng, J. et al. Overexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growth. Cancer Res. 62, 4157-4163 (2002).
132. Garcia-Espana, A., Salazar, E., Sun, T. T., Wu, X. R. & Pellicer, A. Differential expression of cell cycle regulators in phenotypic variants of transgenically induced bladder tumors: implications for tumor behavior. Cancer Res. 65, 1150-1157 (2005).
133. Mo, L. et al. Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. J. Clin. Invest. 117, 314-325 (2007).
134. Gao, J. et al. p53 deficiency provokes urothelial proliferation and synergizes with activated Ha-ras in promoting urothelial tumorigenesis. Oncogene 23, 687-696 (2004).
135. Ahmad, I. et al. β-Catenin activation synergizes with PTEN loss to cause bladder cancer formation. Oncogene 30, 178-189 (2011).
136. Ahmad, I. et al. Ras mutation cooperates with β-catenin activation to drive bladder tumourigenesis. Cell Death Dis. 2, e124 (2011).
137. Ahmad, I. et al. K-Ras and β-catenin mutations cooperate with Fgfr3 mutations in mice to promote tumorigenesis in the skin and lung, but not in the bladder. Dis. Model Mech. 4, 548-555 (2011).
138. Rampias, T. et al. A new tumor suppressor role for the Notch pathway in bladder cancer. Nature Med. 20, 1199-1205 (2014).
139. Foth, M. et al. Fibroblast growth factor receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice. J. Pathol. 233, 148-158 (2014).
140. Shorning, B. Y., Griffiths, D. & Clarke, A. R. Lkb1 and Pten synergise to suppress mTOR-mediated tumorigenesis and epithelial-mesenchymal transition in the mouse bladder. PLoS One 6, e16209 (2011).
141. Tsuruta, H. et al. Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients. Cancer Res. 66, 8389-8396 (2006).
142. Santos, M. et al. In vivo disruption of an Rb-E2F-Ezh2 signaling loop causes bladder cancer. Cancer Res. 74, 6565-6577 (2014).
143. Yang, X. et al. Simultaneous activation of Kras and inactivation of p53 induces soft tissue sarcoma and bladder urothelial hyperplasia. PLoS One 8, e74809 (2013).
144. Seager, C. M. et al. Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer. Cancer Prev. Res. 2, 1008-1014 (2009).
145. Delto, J. C., Kobayashi, T., Benson, M., McKiernan, J. & Abate-Shen, C. Preclinical analyses of intravesical chemotherapy for prevention of bladder cancer progression. Oncotarget 4, 269-276 (2013).
146. Lin, J. H., Zhao, H. & Sun, T. T. A tissue-specific promoter that can drive a foreign gene to express in the suprabasal urothelial cells of transgenic mice. Proc. Natl Acad. Sci. USA 92, 679-683 (1995).
147. Saam, J. R. & Gordon, J. I. Inducible gene knockouts in the small intestinal and colonic epithelium. J. Biol. Chem. 274, 38071-38082 (1999).
148. Bex, A., Vooijs, M., Horenblas, S. & Berns, A. Controlling gene expression in the urothelium using transgenic mice with inducible bladder specific Cre-lox recombination. J. Urol. 168, 2641-2644 (2002).
149. Seager, C., Puzio-Kuter, A. M., Cordon-Cardo, C., McKiernan, J. & Abate-Shen, C. Mouse models of human bladder cancer as a tool for drug discovery. Curr. Protoc. Pharmacol. Unit14.14 (2010).
150. Yoo, L. I. et al. Pten deficiency activates distinct downstream signaling pathways in a tissue-specific manner. Cancer Res. 66, 1929-1939 (2006).
151. Ozaki, K. et al. High susceptibility of p53+/- knockout mice in N-butyl-N-(4-hydroxybutyl)nitrosamine urinary bladder carcinogenesis and lack of frequent mutation in residual allele. Cancer Res. 58, 3806-3811 (1998).
152. Hamed, S. et al. Accelerated induction of bladder cancer in patched heterozygous mutant mice. Cancer Res. 64, 1938-1942 (2004).
153. Hoogervorst, E. M. et al. p53 heterozygosity results in an increased 2-acetylaminofluorene-induced urinary bladder but not liver tumor response in DNA repair-deficient Xpa mice. Cancer Res. 64, 5118-5126 (2004).
154. Hikosaka, A. et al. Susceptibility of p27kip1 knockout mice to urinary bladder carcinogenesis induced by N-butyl-N-(4-hydroxybutyl)nitrosamine may not simply be due to enhanced proliferation. Int. J. Cancer 122, 1222-1228 (2008).
155. Ho, P. L., Lay, E. J., Jian, W., Parra, D. & Chan, K. S. Stat3 activation in urothelial stem cells leads to direct progression to invasive bladder cancer. Cancer Res. 72, 3135-3142 (2012).
156. Said, N., Frierson, H. F., Sanchez-Carbayo, M., Brekken, R. A. & Theodorescu, D. Loss of SPARC in bladder cancer enhances carcinogenesis and progression. J. Clin. Invest. 123, 751-766 (2013).
157. Nishizawa, K. et al. Thioredoxin-interacting protein suppresses bladder carcinogenesis. Carcinogenesis 32, 1459-1466 (2011).
158. Hursting, S. et al. Urothelial overexpression of insulin-like growth factor-1 increases susceptibility to p-Cresidine-induced bladder carcinogenesis in transgenic mice. Mol. Carcinogen. 48, 671-677 (2009).
159. Mo, L., Cheng, J., Lee, E. Y., Sun, T. T. & Wu, X. R. Gene deletion in urothelium by specific expression of Cre recombinase. Am. J. Physiol. Renal Physiol. 289, F562-568 (2005).
160. Shen, T. H. et al. A BAC-based transgenic mouse specifically expresses an inducible Cre in the urothelium. PLoS One 7, e35243 (2012).